ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 18.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,999 shares of the specialty pharmaceutical company’s stock after acquiring an additional 793 shares during the quarter. Teacher Retirement System of Texas’ holdings in ANI Pharmaceuticals were worth $276,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ANIP. JPMorgan Chase & Co. grew its holdings in shares of ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after acquiring an additional 299 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of ANI Pharmaceuticals by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 250,346 shares of the specialty pharmaceutical company’s stock worth $14,936,000 after acquiring an additional 8,869 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of ANI Pharmaceuticals by 14.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock valued at $854,000 after acquiring an additional 1,972 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock valued at $25,373,000 after purchasing an additional 17,314 shares during the period. 76.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ANIP has been the topic of several recent research reports. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price target for the company. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price target for the company. Finally, Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ:ANIP opened at $68.02 on Wednesday. The firm has a 50 day simple moving average of $60.85 and a 200-day simple moving average of $58.57. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.00. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $1.48 billion, a PE ratio of -123.67 and a beta of 0.63.

Insider Buying and Selling

In other news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares in the company, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock worth $191,776 in the last ninety days. 12.70% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.